CD34 and lymphoma: The international phase I/II MOZAIC study was conducted in children (1 to <18 years) with solid tumors, including neuroblastoma, sarcoma, medulloblastoma, or lymphoma, and found that plerixafor plus standard mobilization (G‐CSF ± chemotherapy) significantly increased the proportion of patients achieving a doubling of the peripheral CD34+ cell count in the 24 h before first apheresis compared with standard mobilization alone.22